Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study
Uldrick TS, Gonçalves PH, Abdul-Hay M, Claeys AJ, Emu B, Ernstoff MS, Fling SP, Fong L, Kaiser JC, Lacroix AM, Lee SY, Lundgren LM, Lurain K, Parsons CH, Peeramsetti S, Ramaswami R, Sharon E, Sznol M, Wang C, Yarchoan R, Cheever MA. Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study. JAMA Oncology 2019, 5: 1332-1339. PMID: 31154457, PMCID: PMC6547135, DOI: 10.1001/jamaoncol.2019.2244.Peer-Reviewed Original ResearchNon-Hodgkin lymphomaSafety of pembrolizumabB-cell lymphoproliferationCells/μLAntiretroviral therapyTumor responseKaposi's sarcomaStable diseaseCD4 countAdverse eventsAdvanced cancerMost treatment-emergent adverse eventsAdverse Events grade 2Anti-PD-1 therapyNCI Common Terminology CriteriaTreatment-emergent adverse eventsActive immunosuppressive therapyCommon Terminology CriteriaGood tumor responseT-cell countsAlanine aminotransferase levelsHIV viral loadPhase 1 studyImmune-related eventsCopies/mL